F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
26 hedge funds and large institutions have $19.4M invested in F-star Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
37% more capital invested
Capital invested by funds: $14.1M → $19.4M (+$5.23M)
24% more funds holding
Funds holding: 21 → 26 (+5)
4.42% more ownership
Funds ownership: 15.8% → 20.22% (+4.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.25M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$728K |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$447K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$346K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$422K |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$255K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$202K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$15K |
| 5 |
BlackRock
New York
|
-$2.88K |
FSTX Hedge Fund Activity: Q1 2021 in Review
26 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2021, worth a combined $19.4M — up 37% from $14.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FSTX positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.36M. The largest seller was Renaissance Technologies, cutting an estimated $422K.
- 26 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $19.4M of F-star Therapeutics, Inc. Common Stock stock for Q1 2021, up 37% quarter-over-quarter.
- 7 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2021 and 2 closed out, a net change of +5 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $1.36M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2021 was Renaissance Technologies, an estimated $422K sold.
Based on aggregated 13F filings for Q1 2021.